COO — The Cooper Companies, Inc.

Sentiment is a tug-of-war: Q2 FY2026 revenue rose ~7.9% YoY to $1.0815B and non-GAAP EPS of $1.21 beat consensus, yet the GAAP quarter swung to a loss on litigation-related charges and full-year organic guidance is only 3.5-6%. Analysts are mostly Buy-rated (16 buy, 8 hold, 1 sell) with a consensus target near $76.80, but recent target cuts and deteriorating technicals keep the market cautious. Net read: constructive fundamentals, lukewarm price action.

Revenue trend is steadily upward and slightly accelerating: quarterly revenue went from ~$930M in Jul-2023 to ~$1.003B in Apr-2025 to $1.0815B in Apr-2026, with the latest quarter up 7.9% YoY. Gross margin has stayed high, around 64-68%. The Apr-2026 quarter's GAAP operating income of -$31M and EPS of -$0.40 are distorted by the CooperSurgical litigation/strategic-review charge, not an operating collapse; the prior three quarters had GAAP operating income of $140M-$213M. So the recent GAAP dip is a one-time blip, not a structural margin break.

On trailing GAAP numbers, COO looks expensive: 60.1x TTM EPS, 1.68x book, 3.27x sales. But TTM GAAP EPS of $1.21 is heavily depressed by litigation and amortization charges. On forward non-GAAP EPS of $4.63, the stock trades at only ~15.3x, well below its 5-year average P/E of ~35.9 and below its 5-year average P/S of 4.85 versus 3.27 now. The deterministic valuation context is 'Neutral vs. its own history,' and the cheap forward multiple reflects decelerating/mid-single-digit growth and APAC headwinds. On balance, I'd call it fairly valued with a modest margin of safety if guidance holds.

At ~15.3x forward non-GAAP EPS, the market is pricing in skepticism that COO can grow much beyond the guided $4.58-4.66 EPS. If Q3 FY2026 (due September 9, 2026) shows APAC stabilization and margin recovery, the stock is underwriting normalized earnings too cheaply. If growth stays tepid or CooperSurgical remains a drag, 15x is simply fair for a mid-single-digit grower. Earnings beat once already; the play is whether that can repeat.

As of 2026-08-27, RSI stood at 38.08—weak but not yet oversold below 30. Price was -5.31% below the 20-day SMA, -1.82% below the 50-day, and -3.37% below the 200-day SMA, so the trend is down and momentum is negative. The 52-week range of $58.89-$89.83 shows the stock is range-bound rather than broken. Entry-timing implication: wait for a reclaim of the 50-day or a deeper washout near the low $60s rather than chasing weakness.

• Persistent APAC softness, especially Japan and China, is capping growth and weighing on sentiment.
• Higher-for-longer interest rates keep med-tech valuations compressed and put a premium on balance-sheet quality.
• Healthcare sector rotation has left COO lagging broader healthcare/XLV year-to-date.
• Litigation/regulatory overhang around CooperSurgical's embryo culture media recall has partially cleared, but regulatory watch continues.
• Demographic tailwinds in myopia management and fertility treatment provide a structural demand floor.

• Q3 FY2026 earnings on September 9, 2026—consensus EPS ~$1.11-1.12; watch APAC commentary and margin trajectory.
• Potential strategic action, partnership, or divestiture involving CooperSurgical now that the litigation overhang is resolved.
• Continued adoption of myopia-management and daily silicone hydrogel contact lenses.
• A recovery in Japan/China demand would likely drive guidance upside.

• APAC consumer weakness persists longer than expected, especially in Japan and China.
• Further litigation, recall, or impairment charges could hit GAAP earnings again.
• Intense competition in contact lenses and fertility/women's health could pressure market share and pricing.
• Mid-single-digit growth leaves limited margin for error—any miss on Q3 or FY guidance could trigger further multiple compression.

COO is not a clear buy or short at $70.96. The franchise is solid—high gross margins, growing demand in contact lenses and fertility, low debt—but growth is mid-single-digit and APAC is soft. At ~15.3x forward EPS, valuation is reasonable, not a screaming bargain, and the market is waiting for proof of sustained acceleration. I lean neutral: hold/accumulate into weakness, and get more constructive on a confirmed APAC inflection or post-Q3 stabilization.

Calculated by applying a 17.5x justified P/E to consensus forward non-GAAP EPS of $4.63 (guidance midpoint $4.58-4.66). 17.5x is a modest premium to the current ~15.3x forward multiple but below historical averages, reflecting mid-single-digit organic growth, high gross margins, low leverage, and lingering APAC uncertainty.